Stockscreener 앱 받기
3.59
7.47%
-0.29
전일 마감가:
$3.88
열려 있는:
$3.9
하루 거래량:
100.54K
Relative Volume:
0.01
시가총액:
$12.78M
수익:
-
순이익/손실:
$-60.61M
주가수익비율:
-3.9889
EPS:
-0.9
순현금흐름:
$-22.91M
1주 성능:
-3.23%
1개월 성능:
+3,319%
6개월 성능:
+385.14%
1년 성능:
+212.17%
1일 변동 폭
$3.5433
$3.92
1주일 범위
$3.5433
$4.17
52주 변동 폭
$0.0815
$4.44
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
BLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.59 | 12.78M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-05-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-02-13 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-08-17 | 재확인 | Maxim Group | Buy |
| 2015-07-27 | 재확인 | ROTH Capital | Buy |
| 2015-06-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - StockTitan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India
BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - StockTitan
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India
BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com
BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks
BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx to Report Q3 2024 Financial Results on November 25 - StockTitan
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Bioline Rx Ltd Adr (BLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):